Erwin P Bottinger | Mount Sinai

Biography

Research Topics

Apoptosis/Cell Death, Bioinformatics, Cell Biology, Diabetes, Fibrosis, Genomics, Growth Factors and Receptors, Kidney, Knockout Mice, Signal Transduction

Research

Early pathomechanisms in diabetic nephropathy and non-diabetic kidney diseases

Millions of Americans are affected with chronic diabetic and non-diabetic kidney diseases that cause kidney failure (end stage renal disease). When kidneys fail, the average life expectancy is just over two years and survival depends on costly and disabling dialysis or transplantation treatments.

State-of-the-art genomics and bioinformatics approaches are used to discover and characterize new molecular targets and pathways associated with apoptosis, transdifferentiation, and fibrogenesis in specialized renal cells exposed to diabetic and other stresses. TGF-beta signaling pathways and targets are a major theme because TGF-beta is a key mediator of these processes.

Model systems used include renal cell culture and mouse models of diabetic and non-diabetic progressive renal disease. A new genomic medicine program aims at identification and validation of molecular biomarkers that predict progressive kidney disease in humans.

Education

Nuremberg General Hospital, University of ErIangen-Nuremberg

Cabrini Medical Center

Massachusetts General Hospital and Harvard Medical School

National Cancer Institute, National Institutes of Health

MD, Friedrich-Alexander Universitat School of Medicine, Erlangen-Nurember

Publications

348

Publications

Selected Publications

A clustering approach to improve our understanding of the genetic and phenotypic complexity of chronic kidney disease. A. Eoli, S. Ibing, C. Schurmann, G. N. Nadkarni, H. O. Heyne, E. Böttinger. Scientific Reports

Genetic sex validation for sample tracking in next-generation sequencing clinical testing. Jianhong Hu, Viktoriya Korchina, Hana Zouk, Maegan V. Harden, David Murdock, Alyssa Macbeth, Steven M. Harrison, Niall Lennon, Christie Kovar, Adithya Balasubramanian, Lan Zhang, Gauthami Chandanavelli, Divya Pasham, Robb Rowley, Ken Wiley, Maureen E. Smith, Adam Gordon, Gail P. Jarvik, Patrick Sleiman, Melissa A. Kelly, Harris T. Bland, Mullai Murugan, Eric Venner, Eric Boerwinkle, Cynthia Prows, Lisa Mahanta, Heidi L. Rehm, Richard A. Gibbs, Donna M. Muzny, Debra J. Abrams, Samuel E. Adunyah, Ladia H. Albertson-Junkans, Berta Almoguera, Paul S. Appelbaum, Samuel Aronson, Sharon Aufox, Lawrence J. Babb, Hana Bangash, Melissa A. Basford, Meckenzie Behr, Barbara Benoit, Elizabeth J. Bhoj, Sarah T. Bland, Kenneth M. Borthwick, Erwin P. Bottinger, Deborah J. Bowen, Mark Bowser, Murray Brilliant, Ali Gharavi, Eimear E. Kenny. BMC Research Notes

Prioritization of Kidney Cell Types Highlights Myofibroblast Cells in Regulating Human Blood Pressure. Mahboube Ganji-Arjenaki, Zoha Kamali, Evangelos Evangelou, Helen R. Warren, He Gao, Georgios Ntritsos, Niki Dimou, Tonu Esko, Reedik Mägi, Lili Milani, Peter Almgren, Thibaud Boutin, Stéphanie Debette, Jun Ding, Franco Giulianini, Elizabeth G. Holliday, Anne U. Jackson, Ruifang Li -Gao, Wei Yu Lin, Jian'an Luan, Massimo Mangino, Christopher Oldmeadow, Bram Peter Prins, Yong Qian, Muralidharan Sargurupremraj, Nabi Shah, Praveen Surendran, Sébastien Thériault, Niek Verweij, Sara M. Willems, Jing Hua Zhao, Philippe Amouyel, John Connell, Renée de Mutsert, Alex S.F. Doney, Martin Farrall, Cristina Menni, Andrew D. Morris, Raymond Noordam, Guillaume Paré, Neil R. Poulter, Denis C. Shields, Alice Stanton, Simon Thom, Gonçalo Abecasis, Najaf Amin, Dan E. Arking, Kristin L. Ayers, Erwin P. Bottinger, Paul F. O'Reilly. Kidney International Reports

View All Publications

Office Locations

Annenberg Building Floor 18 Room 16

1468 Madison Ave

New York, NY 10029

212-241-0800

Industry Relationships

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Bottinger has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.

Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.

Dr. Bottinger has not yet completed reporting of Industry relationships.

Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.